FLASH Pre Clinical Dosimetry

最近的超高剂量率放射研究表明，与传统的剂量率放射治疗(几个剂量/分钟)相比，在保持相似的肿瘤反应的同时，被称为闪光放射治疗(RT)的超高剂量率放射治疗(UHDR；40GY/S)显著降低了正常组织毒性(称为闪光效应)。这可能代表着癌症治疗的一步改变，对患者和医疗保健提供者有重大好处。然而，支持闪光效应的机制仍不清楚。广泛的临床前放射研究对于充分了解这一现象并验证临床试验的方法是必要的。Xstrahl开发了一种临床前闪光放射治疗系统，使领先的癌症研究团队能够进行精确的闪光检查。。两个英国中心(癌症研究所和贝尔法斯特皇后大学)购买了我们的两个首批SARRP闪存系统，作为最近MRC赠款(投资世界级实验室)的一部分。现在至关重要的是，我们必须开发一种方法来进行准确和可追踪的剂量测量，并拥有合适的探测器来测量闪光区域的辐射剂量，该辐射剂量在毫秒而不是几分钟内传递。目前还没有现成的剂量计为临床前的光子闪光放射治疗提供准确的剂量测量，闪光放射治疗的剂量学标准仍在不断涌现。癌症研究团队需要准确地知道提供给他们的样本的剂量，才能使闪光研究有效，并在英国研究小组和世界范围内复制。这对于避免对临床前研究的错误解释、降低临床试验的风险和加速闪光治疗的临床采用也是至关重要的。有了国家物理实验室的专家团队，我们有机会在世界范围内的其他测量标准实验室中率先定义临床前或一般闪光剂量测量。作为一家英国制造商，这让我们走在了这项技术的前沿。作为第一家开发和向市场推出临床前光子闪光系统的制造商，作为此次通话的一部分而开发的剂量测量系统将是世界上第一个。这将使我们能够为更广泛的研究基础提供我们的解决方案，并有助于加快将闪光放射治疗引入临床实践。

Recent radiation studies with ultra-high dose rates, UHDR, (\>40 Gy/s), known as FLASH radiotherapy (RT), have demonstrated a remarkable reduction in normal tissue toxicity (known as the "FLASH effect") with respect to conventional dose-rate radiotherapy (few Gy/min) while maintaining similar tumour response. This could represent a step-change in cancer treatment with significant benefits for patients and healthcare providers. However, the mechanisms underpinning the FLASH effect are still unknown. Extensive pre-clinical radiation studies are necessary to gain the full understanding of this phenomenon and validate the approach for clinical trials.Xstrahl has developed a pre-clinical FLASH radiotherapy system to enable leading cancer research teams to perform precise FLASH investigations. . Two UK centres (Institute of Cancer Research and Queens University Belfast) purchased our two first SARRP FLASH systems as part of the recent MRC grant (Investment in World Class Labs). It is now essential that we develop a methodology to carry out the accurate and traceable dosimetry and have suitable detectors to measure the radiation dose in the FLASH regime, which is delivered within milliseconds rather than minutes. No current off-the-shelf dosimeters are available to provide accurate dose measurements for pre-clinical photon FLASH RT, and the dosimetry standards for FLASH radiotherapy are still emerging. The cancer research teams need to know accurately the dose delivered to their samples for FLASH research to be valid and reproduced across the UK research groups and world-wide. This is also essential to avoid flawed interpretation of the pre-clinical studies, de-risking clinical trials and accelerate clinical adoption of FLASH treatments.With the team of experts form the National Physical Laboratory, we have the opportunity to pioneer how pre-clinical or general FLASH dosimetry is defined world-wide across other measurement standard laboratories. That puts us, as a UK manufacturer, on the forefront of this technology. As the first manufacturer to develop and introduce on the market a pre-clinical photon FLASH system, the dosimetry system to be developed as part of this call will be the world's first. This will enable us to provide our solution to a wider research base and help accelerate the introduction of FLASH radiotherapy to clinical practice.